Recent News

• 03.03.2025 - Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders
• 02.28.2025 - Nexalin Technology Announces Initiation of Patient Recruitment for UCSD’s TBI & PTSD Clinical Study Following IRB Approval
• 02.26.2025 - Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board
• 02.19.2025 - Inside Nexalin: CEO Mark White on TBI Solutions & Expanding Market Potential
• 02.10.2025 - Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition
• 02.03.2025 - Nexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study
• 02.03.2025 - Nexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study
• 01.23.2025 - Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session, Today, January 23

Recent Filings

• 02.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.10.2025 - 5 Annual statement of changes in beneficial ownership of securities
• 02.06.2025 - 8-K Current report
• 02.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.03.2025 - EFFECT Notice of Effectiveness
• 01.30.2025 - S-1/A General form for registration of securities under the Securities Act of 1933
• 01.29.2025 - 5 Annual statement of changes in beneficial ownership of securities
• 01.29.2025 - 5 Annual statement of changes in beneficial ownership of securities